TJTharusha Jayasena

Tharusha Jayasena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tharusha Jayasena has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extreme Conservation and Rare Evolutionary Deviations in Mammalian NOTCH3 Challenge Current Models of CADASIL Pathogenicity

    by Khawar Sohail Siddiqui, Haluk Ertan, Yi Ren, Anne Poljak, Tharusha Jayasena, Perminder Sachdev

    NOTCH3 is a highly conserved transmembrane receptor implicated in CADASIL, a hereditary small-vessel disease caused predominantly by mutations affecting its extracellular EGF-like repeats. The mechanisms by which these muta-tions cause pathology remain incompletely understood. We present the first large-scale comparative bioinformatics and molecular dynamics (MD) analysis of NOTCH3 across 113 mammalian species, revealing three novel findings: (i) near-complete conservation of all 204 cysteine residues, with the only exception being eight naturally occurring cysteine substitutions in jaguar EGFr13–15; (ii) a unique deletion within the regulatory region of Brandt’s bat that may increase protease accessibility and alter receptor signaling; and (iii) a rare human NOTCH3-X1 isoform, absent from most mam-mals but shared with select primates, a bat, and elephants, involving a cysteine-depleting deletion spanning EGFr20–22. These naturally occurring exceptions demonstrate that alterations predicted to be deleterious under current pathogenic-ity models can be tolerated in specific evolutionary contexts. Together, these findings provide new insights into the structure–function relationships of NOTCH3, refine the interpretation of CADASIL-associated variants, and identify testable targets for future experimental studies. Our study highlights the power of comparative bioinformatics to uncover previously unrecognized functional features in disease-associated mammalian proteins.

  • Open Access

    Enzymes Drive Glutathione Shunt to Explain Oxidative State Using an In-Parallel Multi-Omic Method

    by Valerie C. Wasinger, Sonia Bustamante, Nashwa Najib, Ashish Diwan, Tharusha Jayasena, Nahian S. Chowdhury, Julia Beretov, Siobhan Schabrun

    The glutathione shunt is one of the most important contributors to the cellular redox state, with implications across cancer, chronic diseases, diseases of ageing, and autoimmune diseases, including inflammatory bowel disease (IBD). Traditionally, the redox state is gauged by the ratio of the surrogate metabolites GSH and GSSG. However, this presents methodological challenges and offers a constrained illustration of metabolites without a systems-level understanding of redox dynamics, failing to elucidate variations across an entire biochemical network. Targeted proteomics can fill this void. Here, we describe an in-parallel metabolomic and proteomic targeted method to encompass measurements directly related to the shunt. Samples are simultaneously prepared to extract the substrate building blocks, cysteine, cystine, methionine, glutamic acid, and kynurenine; and the proteins, SLC7A11 (xCT), Glutamate Cysteine Ligase (GSH1), Glutathione Synthetase (GSH2), Glutathione Peroxidase (GPx), and Glutathione Reductase (GSHR) for targeted mass spectrometry. We demonstrate the method by targeted analysis of proteins in plasma, serum, nasal swab, and saliva and apply the multi-omic method to assess changes in the glutathione shunt in the serum of patients diagnosed with IBD. This allows for a broader narrative to establish context at which the glutathione shunt is operating.


  • Assay of Fatty Acids and Their Role in the Prevention and Treatment of COVID-19

    by Tharusha Jayasena, Sonia Bustamante, Anne Poljak, Perminder Sachdev

    Since the emergence of COVID-19, concerted worldwide efforts have taken place to minimize global spread of the contagion. Its widespread effects have also facilitated evolution of new strains, such as the delta and omicron variants, which emerged toward the end of 2020 and 2021, respectively. While these variants appear to be no more deadly than the previous alpha, beta, and gamma strains, and widespread population vaccinations notwithstanding, greater virulence makes the challenge of minimizing spread even greater. One of the peculiarities of this virus is the extreme heath impacts, with the great majority of individuals minimally affected, even sometimes unaware of infection, while for a small minority, it is deadly or produces diverse long-term effects. Apart from vaccination, another approach has been an attempt to identify treatments, for those individuals for whom the virus represents a threat of particularly severe health impact(s). These treatments include anti-SARS-CoV-2 monoclonal antibodies, anticoagulant therapies, interleukin inhibitors, and anti-viral agents such as remdesivir. Nutritional factors are also under consideration, and a variety of clinical trials are showing promise for the use of specific fatty acids, or related compounds such as fat-soluble steroid vitamin D, to mitigate the more lethal aspects of COVID-19 by modulating inflammation and by anti-viral effects. Here we explore the potential protective role of fatty acids as a potential prophylactic as well as remedial treatment during viral infections, particularly COVID-19. We present a multiplexed method for the analysis of free and phospholipid bound fatty acids, which may facilitate research into the role of fatty acids as plasma biomarkers and therapeutic agents in minimizing pre- and post-infection health impacts. Key words COVID-19 Fatty acid Mass spectrometry Quantitation Plasma

  • Glutamate in the Pathogenesis of Gliomas

    by Nady Braidy, Anne Poljak, Tharusha Jayasena, Seray Adams, Perminder Sachdev